Your browser is no longer supported. Please, upgrade your browser.
Annexon, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own- Shs Outstand28.46M Perf Week6.53%
Market Cap1.11B Forward P/E- EPS next Y-1.70 Insider Trans- Shs Float21.19M Perf Month38.07%
Income-56.40M PEG- EPS next Q-0.44 Inst Own95.70% Short Float3.10% Perf Quarter23.89%
Sales- P/S- EPS this Y-107.10% Inst Trans4.56% Short Ratio4.29 Perf Half Y17.51%
Book/sh12.84 P/B2.42 EPS next Y54.90% ROA-37.80% Target Price35.33 Perf Year-
Cash/sh10.38 P/C2.99 EPS next 5Y38.60% ROE-649.20% 52W Range15.33 - 38.01 Perf YTD23.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.42% Beta-
Dividend %- Quick Ratio41.60 Sales past 5Y- Gross Margin- 52W Low102.28% ATR3.14
Employees38 Current Ratio41.60 Sales Q/Q- Oper. Margin- RSI (14)58.82 Volatility13.28% 12.06%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.41 Prev Close29.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume153.13K Price31.01
Recom1.70 SMA207.45% SMA5016.83% SMA20023.23% Volume214,777 Change6.89%
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
Mar-01-21 01:11PM  
Feb-08-21 07:00AM  
Jan-12-21 07:00AM  
Jan-05-21 07:00AM  
Dec-21-20 07:00AM  
Dec-11-20 01:15PM  
Nov-16-20 04:01PM  
Nov-12-20 04:05PM  
Oct-24-20 10:13AM  
Sep-08-20 04:01PM  
Jul-30-20 08:00AM  
Jul-28-20 04:05PM  
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.